Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital ...